Effects of methylphenidate on weight gain and food intake in hypothalamic obesity

Frontiers in Endocrinology

Volumn 2, Issue DEC, 2011, Pages

  Elfers, ClintonThomas ^a   Roth, Christian Ludwig ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Food intake; Hyperphagia; Hypothalamic lesion; Methylphenidate; Weight gain

Indexed keywords

EID: 84874354301     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2011.00078     Document Type: Article

References (33)

1. Ahmet, A., Blaser, S., Stephens, D., Guger, S., Rutkas, J. T., and Hamilton, J. (2006). Weight gain in craniopharyngioma-amodelfor hypothalamic obesity. J. Pediatr. Endocrinol. Metab. 19, 121-127.
2. Brauner, R., Malandry, F., Rappaport, R., Pierre-Kahn, A., and Hirsch, J. F. (1987). Craniopharyn- gioma in children. Endocrine evaluation and treatment. Apropos of 37 cases. Arch. Fr. Pediatr. 44, 765-769.
3. Crawford, C. A., McDougall, S. A., Meier, T. L., Collins, R. L., and Watson, J. B. (1998). Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinase A and dopamine-stimulated adenylyl cyclase activity in the dorsal striatum. Psychopharmacology (Berl.) 136, 34-43.
4. Danielsson, P., Janson, A., Norgren, S., and Marcus, C. (2007). Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. J. Clin. Endocrinol. Metab. 92, 4101-4106.
5. Davis, C., Fattore, L., Kaplan, A. S., Carter, J. C., Levitan, R. D., and Kennedy, J. L. (2011). The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults. Int. J. Neuropsychopharmacol. 7, 1-7.
6. Dawson, R. Jr., Simpkins, J. W., and Wallace, D. R. (1989). Age- and dose-dependent effects of neonatal monosodium glutamate (MSG) administration to female rats. Neurotoxicol. Teratol. 11, 331-337.
7. Elfers, C., Ralston, M., and Roth, C. L. (2011). Studies of different female rat models of hypothalamic obesity. J. Pediatr. Endocrinol. Metab. 24, 131-137.
8. Eyal, O., Sundararajan, S., Inge, T. H., and Rose, S. R. (2006). Obesity in patients with craniopharyngioma. Endocrinologist 16, 286-293.
9. Gerasimov, M. R., Franceschi, M., Volkow, N. D., Gifford, A., Gatley, S. J., Marsteller, D., Molina, P. E., and Dewey, S. L. (2000). Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J. Pharmacol. Exp. Ther. 295, 51-57.
10. Goldfield, G. S., Lorello, C., and Doucet, E. (2007). Methylphenidate reduces energy intake and dietary fat intake in adults: a mechanism of reduced reinforcing value of food? Am. J. Clin. Nutr. 86, 308-315.
11. Hamilton, J. K., Conwell, L. S., Syme, C., Ahmet, A., Jeffery, A., and Daneman, D. (2011). Hypothalamic obesity following craniopharyngioma surgery: results of a pilot trial of combined diazoxide and metformin therapy. Int. J. Pediatr. Endocrinol. 2011, 417949.
12. Kuczenski, R., and Segal, D. S. (2002). Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J. Neurosci. 22, 7264-7271.
13. Leddy, J. J., Epstein, L. H., Jaroni, J. L., Roemmich, J. N., Paluch, R.A., Goldfield, G. S., and Lerman, C. (2004). Influence of methylphenidate on eating in obese men. Obes. Res. 12, 224-232.
14. Leddy, J. J., Waxmonsky, J. G., Salis, R. J., Paluch, R. A., Gnagy, E. M., Mahaney, P., Erbe, R., Pelham, W. E., and Epstein, L. H. (2009). Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. J. Child Adolesc. Psychopharmacol. 19, 127-136.
15. Leitner, C., and Bartness, T. J. (2008). Food deprivation-induced changes in body fat mobilization after neonatal monosodium glutamate treatment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R775-R783.
16. Lustig, R. H., Hinds, P. S., Ringwald-Smith, K., Christensen, R. K., Kaste, S. C., Schreiber, R. E., Rai, S. N., Lensing, S. Y., Wu, S., and Xiong, X. (2003). Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 88, 2586-2592.
17. Mason, P. W., Krawiecki, N., and Meacham, L. R. (2002). The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch. Pediatr. Adolesc. Med. 156, 887-892.
18. McDougall, S. A., Collins, R. L., Karper, P. E., Watson, J. B., and Crawford, C. A. (1999). Effects of repeated methylphenidate treatment in the young rat: sensitization of both locomotor activity and stereotyped sniffing. Exp. Clin. Psychopharmacol. 7, 208-218.
19. Meririnne, E., Kankaanpaa, A., and Seppala, T. (2001). Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1- and D2-receptor antagonists. J. Pharmacol. Exp. Ther. 298, 539-550.
20. Muller, H. L. (2008). Childhood craniopharyngioma. Recent advances in diagnosis, treatment and follow-up. Horm. Res. 69, 193-202.
21. Roth, C. L., Blevins, J. E., Ralston, M., Elfers, C., Ogimoto, K., Kaiyala, K. J., and Morton, G. J. (2011a). A novel rodent model that mimics the metabolic sequelae of obese craniopharyngioma patients. Pediatr. Res. 69, 230-236.
22. Roth, C. L., Gebhardt, U., and Muller, H. L. (2011b). Appetite-regulating hormone changes in patients with craniopharyngioma. Obesity (Silver Spring) 19, 36-42.
23. Roth, T. (2007). Narcolepsy: treatment issues. J. Clin. Psychiatry 68(Suppl. 13), 16-19.
24. Schoelch, C., Hubschle, T., Schmidt, I., and Nuesslein-Hildesheim, B. (2002). MSG lesions decrease body mass of suckling-age rats by attenuating circadian decreases of energy expenditure. Am. J. Physiol. Endocrinol. Metab. 283, E604-E611.
25. Sorva, R. (1988). Children with craniopharyngioma. Early growth failure and rapid postoperative weight gain. Acta Paediatr. Scand. 77, 587-592.
26. Teo, S., Stirling, D., Thomas, S., Hoberman, A., Kiorpes, A., and Khetani, V. (2002). A 90-day oral gavage toxicity study of D-methylphenidate and D, L-methylphenidate in Sprague-Dawley rats. Toxicology 179, 183-196.
27. Teo, S. K., Stirling, D. I., Hoberman, A. M., Christian, M. S., Thomas, S. D., and Khetani, V. D. (2003). D-methylphenidate and D, L-methylphenidate are not developmental toxicants in rats and rabbits. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 162-171.
28. Tokunaga, K., Bray, G. A., and Matsuzawa, Y. (1993). Improved yield of obese rats using a double coordinate system to locate the ventromedial or paraventricular nucleus. Brain Res. Bull. 32, 191-194.
29. Tokunaga, K., Matsuzawa, Y., Fujioka, S., Kobatake, T., Keno, Y., Odaka, H., Matsuo, T., and Tarui, S. (1991). PVN-lesioned obese rats maintain ambulatory activity and its circadian rhythm. Brain Res. Bull. 26, 393-396.
30. Volkow, N. D., Tomasi, D., Wang, G. J., Telang, F., Fowler, J. S., Wang, R. L., Logan, J., Wong, C., Jayne, M., and Swanson, J. M. (2009). Hyperstimulation of striatal D2 receptors with sleep deprivation: implications for cognitive impairment. Neuroimage 45, 1232-1240.
31. Wang, G. J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusil, N., and Fowler, J. S. (2001). Brain dopamine and obesity. Lancet 357, 354-357.
32. Wilens, T. E. (2008). Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J. Clin. Psychopharmacol. 28, S46-53.
33. Yang, P. B., Swann, A. C., and Dafny, N. (2006). Dose-response characteristics of methylphenidate on locomotor behavior and on sensory evoked potentials recorded from the VTA, NAc, and PFC in freely behaving rats. Behav. Brain Funct. 2, 3.